Results 61 to 70 of about 983,540 (218)

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial [PDF]

, 2022
This cohort study assesses the durability of protection against symptomatic COVID-19 among participants of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine ...
Baden, Lindsey R., Corey, Lawrence, COVE Study Group, El Sahly, Hana M., Essink, Brandon, Lin, Dan-Yu, Miller, Jacqueline, Neuzil, Kathleen M.   +7 more
core   +2 more sources

GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine

Frontiers in Genetics, 2022
Background: Immune responses following vaccination against COVID-19 with different vaccines and the waning of immunity vary within the population. Genetic host factors are likely to contribute to this variability.
Ieva Čiučiulkaitė, B. Möhlendick, Laura Thümmler, Neslinur Fisenkci, C. Elsner, U. Dittmer, W. Siffert, M. Lindemann   +7 more
semanticscholar   +1 more source

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Microbiology Spectrum, 2021
Studies examining antibody responses by vaccine brand are lacking and may be informative for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to assess IgG antibody responses following immunization with BNT162b2 (30 μg ...
José G. Montoya, Amy E. Adams, Valérie Bonetti, Sien Deng, Nan A. Link, Suzanne Pertsch, Kjerstie Olson, Martina Li, Ellis C. Dillon, Dominick L. Frosch   +9 more
doaj   +1 more source

Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection [PDF]

, 2023
BACKGROUND AND AIMS: The BNT162b2 and mRNA-1273 COVID-19 vaccines are efficacious in patients with inflammatory bowel disease; but there is a lack of data examining if holding immunosuppressive therapy around vaccination improves immune response.
Cross, Raymond K, Farraye, Francis A, Hashash, Jana G, Kappelman, Michael D, Long, Millie D, Motwani, Kiran K, Weaver, Kimberly N, Zhang, Xian   +7 more
core   +2 more sources

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

The Lancet Regional Health - Europe, 2021
Background Dialysis and kidney transplant patients are vulnerable populations for COVID-19 related disease and mortality. Methods We conducted a prospective study exploring the eight week time course of specific cellular (interferon-γ release assay and ...
J. Stumpf, Torsten Siepmann, T. Lindner, C. Karger, J. Schwöbel, Leona Anders, R. Faulhaber-Walter, J. Schewe, Heike Martin, H. Schirutschke, K. Barnett, J. Hüther, P. Müller, T. Langer, Thilo Pluntke, Kirsten Anding-Rost, Frank Meistring, T. Stehr, Annegret Pietzonka, Katja Escher, Simon Cerny, H. Rothe, F. Pistrosch, Harald Seidel, A. Paliege, J. Beige, Ingolf Bast, A. Steglich, Florian Gembardt, Friederike Kessel, H. Kröger, P. Arndt, Jan Sradnick, Kerstin Frank, A. Klimova, René Mauer, X. Grählert, M. Anft, A. Blazquez-Navarro, T. Westhoff, U. Stervbo, T. Tonn, N. Babel, C. Hugo   +43 more
semanticscholar   +1 more source

Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient [PDF]

, 2022
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are considered the cornerstone of the solution to the current global pandemic.
Cernada, J, Coutinho, RM, Moreira, A, Mota, D, Rama, TA   +4 more
core   +1 more source

Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

medRxiv, 2021
BACKGROUND: Information is limited on messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection or attenuating disease when administered in real-world conditions ...
M. Thompson, J. Burgess, A. Naleway, Harmony L. Tyner, Sarang K. Yoon, J. Meece, Lauren E. W. Olsho, A. Caban-Martinez, A. Fowlkes, K. Lutrick, H. Groom, K. Dunnigan, M. Odean, K. Hegmann, Elisha L Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, L. Grant, K. Ellingson, J. Kuntz, Tnelda Zunie, M. Thiese, L. Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, J. Gerald, Rachel T. Brown, Meghan K Herring, G. Joseph, S. Beitel, Tyson Morrill, Josephine Mak, Patrick Rivers, Brandon Poe, Brian Lynch, Yingtao Zhou, Jing Zhang, A. Kelleher, Yan Li, Monica Dickerson, Erika N Hanson, Kyley Guenther, S. Tong, A. Bateman, E. Reisdorf, J. Barnes, E. Azziz‐Baumgartner, D. Hunt, Melissa L. Arvay, P. Kutty, A. Fry, M. Gaglani   +56 more
semanticscholar   +1 more source

Risk of myocarditis following sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex [PDF]

, 2022
Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.
Channon, Keith M, Coupland, Carol AC, Dixon, Sharon, Handunnetthi, Lahiru, Harnden, Anthony, Hippisley-Cox, Julia, Khunti, Kamlesh, Mei, Xue W, Mills, Nicholas L, Patone, Martina, Shankar-Hari, Manu, Sheikh, Aziz, Watkinson, Peter, Zaccardi, Francesco   +13 more
core   +1 more source

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

New England Journal of Medicine, 2020
Immunogenicity and Moderna’s SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers...
A. Widge, N. Rouphael, L. Jackson, E. Anderson, P. Roberts, M. Makhene, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, Bob C. Lin, N. Doria-Rose, S. O'Dell, S. Schmidt, K. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, Kaitlyn A. Cross, V. Edara, K. Floyd, M. Suthar, Wendy L. Buchanan, C. Luke, J. Ledgerwood, J. Mascola, B. Graham, J. Beigel   +30 more
semanticscholar   +1 more source

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

New England Journal of Medicine, 2022
BACKGROUND: The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. METHODS: Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was
E. Anderson, C. Creech, V. Berthaud, Arin Piramzadian, K. Johnson, M. Zervos, Fredric C. Garner, C. Griffin, Khozema Palanpurwala, M. Turner, Jeffrey Gerber, Richard L Bennett, K. Ali, Madhavi Ampajwala, Gary Berman, J. Nayak, Carey Chronis, Barbara Rizzardi, W. Muller, Christopher A. Smith, G. Fuchs, Daniel S Hsia, J. Tomassini, D. DeLucia, C. Reuter, B. Kuter, Xiaoping Zhao, W. Deng, Honghong Zhou, Daniela Ramirez Schrempp, K. Hautzinger, B. Girard, K. Slobod, R. McPhee, R. Pajon, Anne Aunins, R. Das, Jacqueline M. Miller, S. Schnyder Ghamloush   +38 more
semanticscholar   +1 more source